Shots:
KaliVir will receive an upfront payment & may be eligible to receive research, development & commercial milestone payments along with tiered royalties on commercial sales of the products developed by both the companies
Roche will receive an exclusive license to discover, develop & commercialize the oncolytic vaccinia virus products generated by KaliVir through its VET platform. Both the companies will work towards advancing KaliVir’s VET platform
KaliVir’s VET platform in combination with genetic modifications enhances the vaccinia viral backbone & also maximizes tumor killing, systemic delivery, & spread
Ref: PR Newswire | Image: KaliVir
